Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Almonty Industries Enters New Phase Following Monumental Share Price Surge

Robert Sasse by Robert Sasse
January 14, 2026
in Analysis, Commodities, Penny Stocks
0
Almonty Stock
0
SHARES
40
VIEWS
Share on FacebookShare on Twitter

After a staggering 840% rally throughout 2025, shares of tungsten producer Almonty Industries are now consolidating as the company undergoes a significant structural realignment. Profit-taking has introduced recent pressure on the stock, but a reshaped shareholder base and the operational launch of a key mine are creating a new foundation for the business. The declining stake of a major investor, Deutsche Rohstoff AG, raises questions about the strategic path forward.

Operational Milestone: Sangdong Mine Begins Commercial Production

The core of Almonty’s transformation is operational. In mid-December 2025, the company initiated commercial production at its Sangdong mine in South Korea. This event marks a pivotal shift from a pure-play development company to a producing mining entity—a change considered fundamental for justifying its current market capitalization of approximately $2.33 billion.

To manage this transition, Almonty has strategically bolstered its executive team. The appointments of Brigadier General (Ret.) Steven L. Allen as Chief Operating Officer and Guillaume Wiesenbach de Lamaziere as Chief Development Officer are aimed at optimizing the supply chain and refining corporate strategy. Beyond the flagship operation in South Korea, the company continues to advance projects in Portugal, Spain, and the United States.

Should investors sell immediately? Or is it worth buying Almonty?

A Shift in Capital Structure and Ownership

Parallel to its operational evolution, Almonty’s capital structure has been reconfigured. A crucial development is the changed position of Deutsche Rohstoff AG, whose shareholding has officially fallen below the key reporting threshold of 10%. This reduction was not the result of a sell-off but a direct consequence of dilution following a capital increase finalized in December.

Through the placement of new shares worth about $129 million, Deutsche Rohstoff AG continues to hold over 20 million shares. However, its proportional stake in the company has decreased to roughly 7.97% on an undiluted basis, highlighting the scale of the recent financing round funding Almonty’s expansion. Additional shares were issued in January under employee programs, and convertible bonds were exchanged for equity, increasing the total number of outstanding shares to over 255 million.

Market Perspective and Investor Focus

Following the substantial share price advances of the previous year, the stock is currently trading between 15% and 19% below its 52-week high. For investors, the focus in the coming weeks will be on the company’s efficiency in ramping up production at Sangdong and the seamless integration of its broader project portfolio. The market is watching to see if the operational cash flow can begin to substantiate the ambitious valuation achieved during last year’s remarkable run.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from February 8 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Micron Stock

Micron Stock Receives Major Analyst Upgrades Amid AI Demand Surge

CureVac Stock

CureVac's Stock Market Journey Concludes Following BioNTech Acquisition

UBS Stock

UBS Shares Face Regulatory Crosswinds Amid Analyst Upgrade

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com